Published Research and Presentations

CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour following orchidectomy (ANZUP 1906)

CLIMATE

2023 ASCO Annual Meeting

02/06/2023

Ciara Conduit, Jeremy Lewin, Aaron R. Hansen, Peter Grimison, James Lynam, Andrew Weickhardt, Phillip Parente, David Campbell, Wei Hong, Gavin Marx, Orlaith Heron, Ben Namdarian, Anna Kuchel, Margaret McJannett, Thomas Cusick, Antoinette Fontela, Sophie O’Haire, Kristina Zlatic, Ian D. Davis, and Ben Tran, on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.

P3 BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs) (TPS5102)

P3BEP

2023 ASCO Annual Meeting

02/06/2023

DS Zebic, B Tran, AJ Martin, FD Pashankar, D Mazhar, RA Huddart, M Wheater, ET Walpole, E Dunwoodie, DR Feldman, AJ Birtle, D Wyld, NJ Lawrence, MR Stockler, PS Grimison on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Adding mitomycin (MM) to Bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non muscle-invasive urothelial bladder cancer (NMIBC) (BCGMM; ANZUP 1301)

BCG+MM

2023 ASCO Annual Meeting

02/06/2023

D Hayne, MR Stockler, AJ Martin, S McCombie, DS Zebic, PA Bastick, EK Beardsley, M Frydenberg, W Green, J Grummet, C Hawks, J Ischia, A Mitterdorfer, M Patel, M Roberts, S Sengupta, RK Srivastav, AD Redfern, ID Davis, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

E: A randomized non-comparative phase II trial of biomarker driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903)

GUIDE

2023 ASCO Annual Meeting

02/06/2023

Ciara Conduit, Blossom Mak, Wenjia Qu, Juliana Di lulio, Ronan Burder, Matthias Bressel, Thomas Cusick, Haryana M Dhillon, Richard De Abreu Lourenço, Craig Underhill, Javier Torres, Megan Crumbaker, Florian Honeyball, Anthony Linton, Sanjeev Sewak, Ray Allen1, Ian D Davis, Susan J Clark, Lisa G Horvath, *, Kate L Mahon, * on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

EVOLUTION: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (ANZUP 2001

EVOLUTION

22/02/2023

Shahneen Sandhu, Shalini Subramaniam Michaels. Kolman. Marfin R. Stockler, Andrew James Martin. Izabella Pokorski Jeffrey C Goh. David A. Pallison. Nattakom Ohiantravan• Craig Gedye Natalie K. Ruthefford Anthony M. Joshua Thean Hsiang Tan'. Ian o. Kirkwood'. Sze Ting Lee, Andrew J. Weickhardt, Ramin Alipaur1, Andrew Nguyen, Ian Davis, Louise Emmett,